Introduction

Capabilities

Cangene's Research and Development group is located in Winnipeg, Manitoba. Incorporating research, full product/process development and non-clinical/clinical skill sets, this experienced group is responsible for discovering and/or developing innovative therapeutic products and technologies, and taking them through to the clinic. The research and development team takes a collaborative approach with internal and external stakeholders to identify viable commercial opportunities. It focuses on early-stage evaluation and development of new products as well as process scale-up, assay development and validation in later stages.

Cangene’s products may arise from internal discovery or through in-licensing. If you are interested in partnering or out-licensing your product(s), please contact our Business Development Group at businessdevelopment@cangene.com

For additional information about our Research and Development capabilities, please contact researchanddevelopment@cangene.com

Pipeline

PRODUCT	DESCRIPTION	INDICATION	RESEARCH/ PRECLINICAL	PHASE I	PHASE II	PHASE III	APPROVED
WinRho® SDF	Hyperimmune: Purified antibodies specific for Rh+ red blood cells (also called anti-D immunoglobulin)	Treating ITP (an autoimmune platelet disorder); preventing hemolytic disease of the newborn; potential usage in infectious diseases that cause a severe drop in platelets
HepaGam B®	Hyperimmune: Purified antibodies specific for hepatitis B virus	Treatment following hepatitis B exposure and following liver transplantation in hepatitis-B-positive patients
VariZIG®	Hyperimmune: Purified antibodies specific for Varicella zoster virus (chickenpox virus)	Preventing or reducing severity of chickenpox during pregnancy
Vaccinia immune globulin intravenous	Hyperimmune: Purified antibodies specific for Vaccinia virus (the virus used to make smallpox vaccine)	Treating severe reactions that may accompany smallpox vaccinations
Botulism antitoxin heptavent	Hyperimmune: Purified antibodies specific for the seven toxins that cause botulism	Treating botulism
Anthrax immune globulin	Hyperimmune: Purified antibodies specific for the toxin produced by Bacillus anthracis, the bacteria that cause anthrax	Treating toxemia associated with inhalational anthrax

The information contained within this annual report is intended as an investor summary only and may not include all relevant safety and risk information. Healthcare professionals are directed to refer to approved labelling and prescribing information for products and not rely on information discussed in this report. Prescribing information or drug names may differ in various countries. Scientific information that relates to unapproved products or unapproved uses of products is preliminary and investigative. No conclusions can or should be drawn regarding the safety or efficacy of such products. Only regulatory authorities can determine whether products are safe and effective for the uses being investigated. No information in this report is intended to promote the products discussed.